A common mRNA modification is 5-methylcytosine (mC), whose role in gene-transcript processing and cancer remains unclear. Here, we identify serine/arginine-rich splicing factor 2 (SRSF2) as a reader of mC and impaired SRSF2 mC binding as a potential contributor to leukemogenesis. Structurally, we identify residues involved in mC recognition and the impact of the prevalent leukemia-associated mutation SRSF2. We show that SRSF2 binding and mC colocalize within transcripts. Furthermore, knocking down the mC writer NSUN2 decreases mRNA mC, reduces SRSF2 binding, and alters RNA splicing. We also show that the SRSF2 mutation impairs the ability of the protein to read mC-marked mRNA, notably reducing its binding to key leukemia-related transcripts in leukemic cells. In leukemia patients, low NSUN2 expression leads to mRNA mC hypomethylation and, combined with SRSF2, predicts poor outcomes. Altogether, we highlight an unrecognized mechanistic link between epitranscriptomics and a key oncogenesis driver.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11090011 | PMC |
| http://dx.doi.org/10.1016/j.molcel.2023.11.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification of the whole genome of alternative splicing and RNA-binding proteins involved in nintedanib-induced apoptosis in gastric cancer cells.
PeerJ
December 2024
The First School of Clinical Medicine, Lanzhou University, LanZhou, Gansu, China.
Background: It has been demonstrated that nintedanib can inhibit the proliferation of gastric cancer cells, but the specific mechanism of action is unclear.
Objective: Investigating the changes of key factors involved in gene transcription and post-transcriptional regulation during the process of treating gastric cancer with nintedanib.
Methods: In this study, we performed transcriptome sequencing on gastric cancer cell groups treated with nintedanib and control groups.
Regulation of AUF1 alternative splicing by hnRNPA1 and SRSF2 modulate the sensitivity of ovarian cancer cells to cisplatin.
Cell Oncol (Dordr)
December 2024
Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Purpose: Clarification of cisplatin resistance may provide new targets for therapy in cisplatin resistant ovarian cancer. The current study aims to explore involvement of isoforms of AU-rich element RNA-binding protein 1 (AUF1) in cisplatin resistance in ovarian cancer.
Methods: The cancer stem cell-like features were analyzed using colony formation assay, tumor sphere formation assay and nude mouse xenograft experiments.
Therapeutic strategies targeting aberrant RNA splicing in myeloid malignancies.
Br J Haematol
December 2024
Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Article Synopsis
- Large-scale sequencing has found driver mutations in haematopoietic stem cells, leading to nine new treatments for relapsed or refractory acute myelogenous leukaemia (R/R AML).
- Despite the progress in targeted therapies, achieving long-term remission in AML and high-risk myelodysplastic syndrome (HR-MDS) is still difficult, highlighting the need for effective new treatments.
- Targeting aberrant RNA splicing is being explored as a promising therapeutic approach, as it contributes to tumor growth, chemotherapy resistance, and other cancer-related issues in various myeloid diseases.
Corrigendum: A novel LncRNA, AC091729.7 promotes sinonasal squamous cell carcinomas proliferation and invasion through binding SRSF2.
Front Oncol
September 2024
Department of Otorhinolaryngology, Head and Neck Surgery, The Second Affiliated Hospital, Harbin Medical University, Harbin, China.
Article Synopsis
- The article is a correction to a previously published study identified by the DOI 10.3389/fonc.2019.01575.
- The correction aims to address issues or errors found in the original research.
- It is part of maintaining academic integrity and ensuring that findings are accurate for future references.
Genomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study.
Int J Mol Sci
September 2024
Department of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Article Synopsis
- Scientists are trying to figure out how to diagnose different types of blood disorders called MDS and MPN, which can be tricky because they have some similar features.
- They looked at the DNA of patients with different types of these disorders to see how they are different and found specific gene mutations that can help identify each type.
- The research shows that age and certain mutations can affect how well patients do, and this information can help doctors make better decisions about treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!